8 results about "Circulating miRNA" patented technology

The invention provides a detection marker and a method for identifying central precocious girls in vitro. According to the detection marker and the method, the expression quantities of has-miR-584-5p, hsa-miR-625-3p and has-miR-7-5p in miRNA markers in serum of the central precocious girls are found to be obviously changed; the miRNA can be used as a biomolecular marker for detecting central precocious girls, and the method is used for second-generation sequencing detection of circulating miRNA in a blood sample of a subject; according to the method, the expression quantity of each miRNA in a test sample is obtained through data analysis, a feature subset is obtained through random forest modeling based on the expression quantity of the miRNA marker, and the accuracy of the miRNA combination is evaluated by calculating the AUC value, so that whether a subject suffers from central precocious puberty or not is judged.

The invention belongs to the technical field of biological detection, and particularly discloses a pair of echinococcosis detection markers based on serum circulating miRNA and application of the echinococcosis detection markers, the detection markers are a combination of miR-192-5p and miR-122-5p, the abundance of the miR-192-5p and the miR-122-5p in the serum of an echinococcosis patient is remarkably reduced, the miR-192-5p and the miR-122-5p are in negative correlation with echinococcosis infection, and the threshold values are 0.35 and 0.04 respectively. During detection, the relative expression level (taking caenorhabditis elegans miR-39-3p as an external reference) of caenorhabditis elegans miR-39-3p in serum is determined through qPCR, and the positive and negative properties are judged according to a threshold value; the area under the ROC curve of the marker combination reaches 0.97, and a double-blind test shows that the positive rate and the negative rate of human and mouse serum detection are 100%. The method solves the problems of missed diagnosis and misdiagnosis in existing echinococcosis detection, can be used for preparing a detection kit, realizes accurate detection, curative effect evaluation and prognosis management of echinococcosis, and has extremely high clinical application value.

The present invention discloses a method for detecting miRNA by using a photonic crystal chip and recombinase polymerase amplification, which belongs to the field of nucleic acid detection. The method of the present invention comprises the following steps: preparing a photonic crystal chip; using two probes to complementarily pair with the target miRNA and then connecting them using SplintR ligase; using the connection product as a template, introducing primers, and causing a recombinase amplification reaction under the action of the recombinase; adding Super GelBlue dye to the recombinase amplification product, dropping it on the photonic crystal chip, and detecting it using a fluorescence measurement device. The method of the present invention has ultra-high sensitivity. Under optimal experimental conditions, the detection limit of miRNA in this method is as low as 0.24aM. The present invention does not require the separation and extraction of circulating miRNA and can be directly used for high-throughput rapid quantitative detection of circulating miRNA in serum samples.

The invention discloses an application of a circulating miRNA (micro Ribonucleic Acid) composition in preparation of a detection product for immune checkpoint inhibitor associated pneumonia. The circulating miRNA is a combination of a serum exosome miR-193a-5p, a serum miR-193a-5p and a serum miR-378a-3p. The combined diagnosis of the three miRNAs can distinguish immune checkpoint inhibitor-associated pneumonia patients and healthy people, and the sensitivity and the specificity are high. Compared with a clinical conventional immune checkpoint inhibitor-related pneumonia marker lymphocyte, the circulating miRNA composition provided by the invention has a better diagnosis effect. The circulating miRNA composition provided by the invention can be used for rapidly and reliably identifying epidemic checkpoint inhibitor-related pneumonia patients, and has high clinical application value and wide application prospect.

The invention belongs to the field of molecular medical diagnosis, and particularly relates to a reagent for detecting peripheral blood miRNA markers of PCNSL and GBM, application and a kit. The invention relates to a reagent for detecting a peripheral blood miRNA (micro Ribonucleic Acid) marker of PCNSL (Procalcitonin Nucleic Acid Lipoprotein) and GBM (Glucose Binding Matrix), wherein the peripheral blood miRNA marker is one or a mixture of at least two of hsa-miR-148a-3p, hsa-miR-142-5p, hsa-miR-1339-5p and hsa-miR-4433b-5p. According to the peripheral blood miRNA marker for detecting the PCNSL and the GBM, provided by the invention, early diagnosis and prediction of the PCNSL and the GBM can be realized by detecting the expression quantity of circulating miRNA in body fluid, and the operation is quicker and more accurate. The four differentially expressed miRNAs are used as biomarkers, show a high expression state in the plasma exosome of a PCNSL patient, and show a low expression state in the plasma exosome of a GBM patient.

The invention relates to the technical field of biomedicine, and particularly discloses a circulating miRNAs marker and application thereof. A gene next generation sequencing technology is adopted, the differential expression level of circulating miRNAs of old hypertension patients and hypertension patients accompanied with left ventricular diastolic insufficiency is analyzed, at least one of miR-19b-3p, miR-21-5p, miR-30e-5p or miR-15a-5p is screened out to serve as a biomarker, and at least one of the miR-19b-3p, the miR-21-5p, the miR-30e-5p and the miR-15a-5p is screened out to serve as the biomarker. The invention further evaluates the diagnostic efficacy of the circulating miRNAs and the combination thereof in senile hypertension accompanied by heart function impairment. As novel biomarkers, the circulating miRNAs and the combination thereof provided by the invention have the characteristics of being minimally invasive, easy to obtain, high in sensitivity, strong in specificity and the like.

The present invention describes a method for diagnosing lung cancer in a subject by detecting specific circulating miRNAs ("c-miR signature") in a biological sample obtained from that subject. Such c-miR signature provides an indication and a prognosis of lung cancer in place of or in addition to alternative known methods, including, but not limited to, low-dose computed tomography (LDCT).

The present disclosure relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.